ArticlePatient preference and adherence2026
Investigating the Risk Factors for Medication Nonadherence in Myasthenia Gravis Patients: Establishing a Nomogram Model.
Article in Patient preference and adherence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Many studies have shown that MG patients often show poor adherence to their medications. Poor adherence may affect disease control, and also put a heavy burden on patients' physical functions and medical costs. Therefore, this study aimed to develop and verify a nomogram for predicting medication adherence in MG patients. Methods: We prospectively reviewed clinical information, demographic data, and medication adherence records for MG patients at Shijiazhuang People's Hospital from January to December 2025. Logistic regression models were used to analyse risk factors related to medication nonadherence among MG patients; based on this analysis, we constructed a nomogram. Internal validation involved the Bootstrap method, while discrimination and accuracy of the nomogram were evaluated through the C-index, area under the receiver operating characteristic (ROC) curve (AUC), and calibration curves. Potential clinical use was confirmed by decision curve analysis (DCA) and clinical impact curves. Results: Our study included 376 patients; 194 (51.60%) had poor compliance. There were 263 MG patients in the training cohort, of which 136 (51.71%) had poor compliance. We included five factors in our model: disease recurrence, insurance type, BMQ necessity, BIPQ cognition, and BIPQ emotion. Our model showed an area under the ROC curve of 0.94 (95% CI: 0.91-0.97), with a sensitivity of 87.5% and specificity of 85.8%. Additionally, DCA and clinical impact curves confirmed the effectiveness of the developed model for predicting medication adherence in MG patients. Conclusion: A successful development and validation of a decision curve model based on five risk factors was achieved, which can be utilised for the home management of MG patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.